Kairos Pharma, Ltd., a privately held clinical stage biotechnology company focused on drug resistance and immunotherapy for cancer, today announced that its activated T cell therapy, KROS 201, has received FDA approval to proceed with a Phase 1 clinical trial in patients with recurrent glioblastoma, a type of brain cancer. The phase I trial is…

eTurboNews 文章仅供订阅者使用。订阅是免费.
订阅者在此登录点击此处免费订阅

从这篇文章中可以得到什么：